Microdose Study of Melphalan, Bortezomib and Dexamethasone
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to identify specific genes that are up- or downregulated in
multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib
(Velcade®) or Dexamethasone (Dexaven®). The study treatment constitutes 1% of the planned
standard myeloma treatment and will be given two hours prior to standard treatment. Blood
samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis.